Aspirin linked to decrease in PCa mortality risk

September 19, 2012

Taking aspirin is associated with a lower risk of death from prostate cancer, especially in men with high-risk disease, according to a recent multicenter study.

Taking aspirin is associated with a lower risk of death from prostate cancer, especially in men with high-risk disease, according to a recent multicenter study.

First author Kevin Choe, MD, of the University of Texas Southwestern Medical Center, Dallas, and co-authors studied approximately 6,000 men in the Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE) database who had prostate cancer treated with surgery or radiotherapy. About 2,200 of the men involved (37%) were receiving anticoagulants. The risk of death from prostate cancer was compared between those taking anticoagulants and those who were not.

The findings, which were published online in the Journal of Clinical Oncology (Aug. 27, 2012), demonstrated that 10-year mortality from prostate cancer was significantly lower in the group taking anticoagulants compared with the non-anticoagulant group: 3% versus 8%, respectively. The risks of cancer recurrence and bone metastasis also were significantly lower.

Further analysis suggested that this benefit was primarily derived from taking aspirin, as opposed to other types of anticoagulants.

"The results from this study suggest that aspirin prevents the growth of tumor cells in prostate cancer, especially in high-risk prostate cancer, for which we do not have a very good treatment currently," Dr. Choe said. "But we need to better understand the optimal use of aspirin before routinely recommending it to all prostate cancer patients."

Go back to this issue of Urology Times eNews.

Related Content

FDA approves androgen inhibitor for metastatic PCa

Genetic link to PCa risk in African-Americans found